HK1095133A1 - Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them - Google Patents

Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them

Info

Publication number
HK1095133A1
HK1095133A1 HK07102213.0A HK07102213A HK1095133A1 HK 1095133 A1 HK1095133 A1 HK 1095133A1 HK 07102213 A HK07102213 A HK 07102213A HK 1095133 A1 HK1095133 A1 HK 1095133A1
Authority
HK
Hong Kong
Prior art keywords
tricyclic derivatives
preparations
pharmaceutically acceptable
pharmaceutical compositions
acceptable salts
Prior art date
Application number
HK07102213.0A
Other languages
English (en)
Inventor
Myung-Hwa Kim
Kwangwoo Chun
Jae-Won Choi
Bo-Young Joe
Sang-Woo Park
Kwang Hee Kim
Byung-Kyu Oh
Jong-Hee Choi
Original Assignee
Je Il Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Je Il Pharmaceutical Co Ltd filed Critical Je Il Pharmaceutical Co Ltd
Publication of HK1095133A1 publication Critical patent/HK1095133A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/22Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/41Y being a hydrogen or an acyclic carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/34Benzoheptalenes; Hydrogenated benzoheptalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK07102213.0A 2003-06-25 2007-02-27 Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them HK1095133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030041547 2003-06-25
PCT/KR2004/001518 WO2004113281A1 (en) 2003-06-25 2004-06-23 Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
HK1095133A1 true HK1095133A1 (en) 2007-04-27

Family

ID=36091400

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102213.0A HK1095133A1 (en) 2003-06-25 2007-02-27 Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them

Country Status (14)

Country Link
US (1) US20070179143A1 (zh)
EP (1) EP1646608B1 (zh)
JP (1) JP4430071B2 (zh)
KR (1) KR100667464B1 (zh)
CN (1) CN100393698C (zh)
AT (1) ATE500216T1 (zh)
AU (1) AU2004249639B2 (zh)
CA (1) CA2531543C (zh)
DE (1) DE602004031621D1 (zh)
DK (1) DK1646608T3 (zh)
ES (1) ES2358801T3 (zh)
HK (1) HK1095133A1 (zh)
RU (1) RU2326864C2 (zh)
WO (1) WO2004113281A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622612B2 (en) 2001-05-28 2009-11-24 Chemtech Research Incorporation Tricyclic derivatives and their use
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
SG179300A1 (en) 2006-02-21 2012-04-27 Toyama Chemical Co Ltd Process for production of 3-[5-[4-cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
KR101077609B1 (ko) 2009-07-08 2011-10-27 제일약품주식회사 트리사이클릭 유도체의 제조방법
PL2470499T3 (pl) * 2009-08-26 2019-11-29 Alberta Health Services Nowe pochodne kolchicyny, sposoby i ich zastosowania
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
KR101130754B1 (ko) * 2010-06-25 2012-03-28 제일약품주식회사 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
JP6019126B2 (ja) 2011-10-07 2016-11-02 エピセントアーレックス・インコーポレイテッドEpicentRx, Inc. 有機ニトロチオエーテル化合物およびその医療用途
KR101494280B1 (ko) * 2012-12-28 2015-02-23 한국화학연구원 콜치신 유도체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CN104649943B (zh) * 2015-01-28 2016-10-05 中国科学院上海高等研究院 秋水仙碱衍生物及其制备方法和应用
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
KR20190040931A (ko) 2016-01-11 2019-04-19 에피센트알엑스, 인코포레이티드 2-브로모-1-(3,3-디니트로아제티딘-1-일)에타논의 정맥내 투여를 위한 조성물 및 방법
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
WO2017207385A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JP7004677B2 (ja) 2016-06-01 2022-01-21 バイエル・アニマル・ヘルス・ゲーエムベーハー 動物におけるアレルギー性および/または炎症性疾患の治療および予防に有用な置換インダゾール
WO2018060174A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
EP3526195A4 (en) 2016-10-14 2020-05-20 EpicentRx, Inc. SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE
US10538503B2 (en) * 2016-10-26 2020-01-21 Ishihara Sangyo Kaisha, Ltd. Method for producing 3-methyl-2-thiophenecarboxylic acid
BR112020000196A2 (pt) 2017-07-07 2020-07-07 Epicentrx, Inc. composições para administração parenteral de agentes terapêuticos
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533675A (en) 1984-04-17 1985-08-06 The United States Of America As Represented By The Department Of Health And Human Services Carbamates of colchicine for treatment of gout
IT1276996B1 (it) * 1995-06-27 1997-11-04 Indena Spa Derivati della colchicina, loro uso e formulazioni che li contengono
IT1291550B1 (it) 1997-04-11 1999-01-11 Indena Spa Derivati della colchicina e della tiocolchicina ad attivita' antinfiammatoria e miorilassante
KR100600158B1 (ko) * 2001-05-28 2006-07-12 주식회사 씨트리 신규한 알카로이드 유도체 및 이를 함유하는 약제학적조성물

Also Published As

Publication number Publication date
EP1646608A4 (en) 2006-11-22
KR20050001383A (ko) 2005-01-06
KR100667464B1 (ko) 2007-01-10
EP1646608A1 (en) 2006-04-19
EP1646608B1 (en) 2011-03-02
CA2531543C (en) 2010-10-12
CN100393698C (zh) 2008-06-11
DE602004031621D1 (de) 2011-04-14
ES2358801T3 (es) 2011-05-13
JP4430071B2 (ja) 2010-03-10
AU2004249639B2 (en) 2008-07-17
JP2007520422A (ja) 2007-07-26
RU2326864C2 (ru) 2008-06-20
DK1646608T3 (da) 2011-06-14
CN1826316A (zh) 2006-08-30
ATE500216T1 (de) 2011-03-15
AU2004249639A1 (en) 2004-12-29
RU2006101987A (ru) 2006-07-10
US20070179143A1 (en) 2007-08-02
WO2004113281A1 (en) 2004-12-29
CA2531543A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
HK1095133A1 (en) Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
TNSN04213A1 (en) High drug load tablet
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
HK1097189A1 (en) Cannabinoid receptor ligands
MXPA05008368A (es) 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
GEP20043250B (en) Use of Indolyl-3-Glyoxylic Acid Derivatives as Anti-tumor Means and Pharmaceutical Compositions Containing the Same
HUP0300798A3 (en) Substituted-triazolopyrimidines and their use as anticancer agents and pharmaceutical compositions containing them
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
SE0302192D0 (sv) Novel compounds
TW200639156A (en) New compounds
WO2001078783A3 (en) Compositions comprising natural agents for treatment of cancer
TW200630343A (en) 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2006113495A3 (en) Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof
MY138923A (en) Combination chemotherapy
WO2005016264A3 (en) Diamine derivatives of quinone and uses thereof
WO2009045053A3 (en) A cancer sensitizer comprising chlorogenic acid
ATE482922T1 (de) Aloe-emodinderivate und deren verwendung in der behandlung von neoplasien
HK1167388A1 (en) Anticancer compound and pharmaceutical composition containing the same
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
TNSN06003A1 (en) Saquinavir mesylate oral dosage form
IL163608A (en) Sulfonanilides are conserved in their amino / amino acids and derivatives, their process, their pharmaceutical preparations, and their conjugated antibodies and their use in the preparation of drugs for the treatment of culture disorders
DE60206940D1 (de) Pektin und ascorbinsäure enthaltende zusammensetzungen
GB2430365B (en) High-purity texaphyrin metal complexes
WO2005032492A3 (en) Site and rate selective prodrug formulations of d609 with antioxidant and anticancer activity

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170623